RecruitingNot ApplicableNCT05945524

Analysis of the Resistance and Sensitivity Mechanisms to Teclistamab by Focusing on Single Immune Cell Examination

Sponsor

University Hospital, Toulouse

Enrollment

100 participants

Start Date

Sep 28, 2023

Study Type

INTERVENTIONAL

Conditions

Multiple Myeloma

Summary

The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating why some people with multiple myeloma (a blood cancer) respond well to a drug called teclistamab while others do not. By examining individual immune cells from patients receiving this treatment, researchers hope to understand the biological mechanisms behind treatment resistance. **You may be eligible if...** - You have been diagnosed with multiple myeloma - You are receiving teclistamab as part of your treatment - You have signed an informed consent form **You may NOT be eligible if...** - You are under a legal protection measure that prevents independent consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBone marrow sampling

Bone marrow sampling collected at 12 weeks after initiation treatment (day 1 cycle 4)

Locations(18)

CHU d'Amiens

Amiens, France, France

CHU de Caen

Caen, France, France

Polyclinique du Parc Drevon

Dijon, France, France

CH Annecy Genevois

Epagny Metz- Tessy, France, France

CHU de Lille

Lille, France, France

Centre Léon Bérard

Lyon, France, France

CHU de Montpellier

Montpellier, France, France

Hôpital Saint-Louis

Paris, France, France

Hôpital Saint-Antoine

Paris, France, France

Hôpital Necker

Paris, France, France

CHU de Bordeaux

Pessac, France, France

CHU de Lyon

Pierre-Bénite, France, France

CHU de Poitiers

Poitiers, France, France

CHU de Rennes

Rennes, France, France

CH Saint-Etienne

Saint-Priest-en-Jarez, France, France

CHU de Toulouse

Toulouse, France, France

CHU de Tours

Tours, France, France

CHRU Nancy

Vandœuvre-lès-Nancy, France, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05945524

Related Trials

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

NCT034128771 location

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT0714985717 locations

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT0726644137 locations

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT0650088438 locations

A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

NCT0703051712 locations